Drug Profile
Human proislet peptide - Nanomix Corporation
Alternative Names: BTI-410; HIP-2B; Pancreate; Proisletide acetate - CureDMLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CureDM
- Developer Nanomix Corporation
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Cell differentiation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In volunteers) in USA (SC, Injection)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Treatment-experienced) in USA (SC, Injection)
- 30 Sep 2021 Human proislet peptide is still in phase I trials for Type-1 diabetes mellitus (In volunteers) in USA (SC) (Boston Therapeutics pipeline, September 2021)